IPP Bureau
Neuberg Diagnostics appoints MS Dhoni as brand ambassador
By IPP Bureau - August 24, 2021
This year, the company plans to set up more than 200 labs and 3000 collection centres across the world and has ended FY 21 with a revenue of Rs 800 crores
13 hospitals across India complete first cycle of PRIME programme
By IPP Bureau - August 24, 2021
BD worked with JCI to create a Gold Standard benchmarked safety program called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME)
DBT-BIRAC supported India’s first m-RNA vaccine gets nod for Phase II/III trial
By IPP Bureau - August 24, 2021
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
Mercer/Mettl facilitates integration of PMGDisha and CoWin
By IPP Bureau - August 24, 2021
As part of the PMGDisha-CoWIN integration, Mercer | Mettl has aggregated the database of 5 crore Aadhaar-authenticated and registered candidates, which is now being utilized to deliver vaccinations to the last mile populace
U.S. FDA approval of KORSUVA injection
By IPP Bureau - August 24, 2021
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
Roche and KeChow to commercialise Zelboraf
By IPP Bureau - August 23, 2021
Shanghai Roche Pharmaceuticals and Shanghai KeChow Pharma, entered into a cooperation agreement to improve market access of Zelboraf in China.
Delfi liquid biopsy shows promise for reducing lung cancer deaths
By IPP Bureau - August 23, 2021
When the Delfi technology was used as a pre-screen to determine if a low dose CT (LDCT), should be performed, the combined approach led to the detection of 90% of lung cancers, including 80% of stage I cancers
SIMS Hospital, Chennai perform rare jaw surgeries
By IPP Bureau - August 23, 2021
Surgeries for the replacement of hip and knee joints have become common, the ones for the replacement of jaw joints and the use of 3D printed custom-made joints are new
Pfizer receives EC approval for XEIJANZ
By IPP Bureau - August 23, 2021
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
Vivera Pharmaceuticals gets US patent for ZICOH
By IPP Bureau - August 23, 2021
The software enables real-time communication between patients, caregivers, physicians, and pharmacists and each cartridge in the device has a unique, traceable serial number registered to the patient
Zydus gets USFDA approval for arthritis drug
By IPP Bureau - August 23, 2021
Zydus was the first to file an ANDA for Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength
Covid-19 severity screening method developed
By IPP Bureau - August 23, 2021
Researchers from IIT Bombay and QIMR Berghofer Medical Research Institute, Australia have developed this method, based on the Agilent Cary 630 FTIR Spectrometer
Quess Corp launch healthcare vertical, signs MoU with AHPI
By IPP Bureau - August 23, 2021
It aims to provide trained healthcare manpower, home care solutions, and end-to-end hospital management services enabling quick & on-demand deployment
QubeHealth ties up with OboPay for seamless medical credit
By IPP Bureau - August 23, 2021
Employees of QubeHealth’s corporate clients draw as much money as they need to instantly pay for any medical emergencies or regular healthcare payments
USFDA grants full approval for Pfizer-BioNTech Covid-19 vaccine
By IPP Bureau - August 23, 2021
The vaccine will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of Covid-19 disease
